in

Vineeta Agarwala on the promise—and limits—of AI in drug discovery

Harmony Internal - McKinsey

Share this email

STILL INTERESTED?

We hope you enjoy hearing from us and want to continue getting the emails you’ve signed up for. Let us know.

Yes, I'm still interested

New from McKinsey & Company

Vineeta Agarwala on the promise—and limits—of AI in drug discovery

By helping us learn from every single patient and every piece of data, AI could enable medical breakthroughs, says Andreessen Horowitz general partner Vineeta Agarwala.

Create new insights

Related Reading

Image of a serious female scientist in a lab coat and protective gloves stands in a modern lab, working on a small HUD or graphic display

The future of biotech: AI-driven drug discovery

‘It will be a paradigm shift’: Daphne Koller on machine learning in drug discovery

Follow our thinking

McKinsey Insights - Get our latest thinking on your iPhone, iPad or Android.

Share these insights

Did you enjoy this newsletter? Forward it to colleagues and friends so they can subscribe too. Was this issue forwarded to you? Sign up for it and sample our 40+ other free email subscriptions here.

This email contains information about McKinsey’s research, insights, services, or events. By opening our emails or clicking on links, you agree to our use of cookies and web tracking technology. For more information on how we use and protect your information, please review our privacy policy.

You received this email because you subscribed to The Next Normal newsletter list.

Manage subscriptions | Unsubscribe

by "McKinsey & Company" <publishing@email.mckinsey.com> - 12:04 - 22 Nov 2022

Archives

in

info@learn.odoo.com

It’s the final countdown! Your last chance to save 40% 🚀

In the metaverse, women are locked out of leadership

Vineeta Agarwala on the promise—and limits—of AI in drug discovery

Vineeta Agarwala on the promise—and limits—of AI in drug discovery